The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditure of $2,693,312 ...

Terumo Blood and Cell Technologies has entered into a memorandum of understanding (MOU) with South Korea’s KBIOHealth to jointly develop workforce training initiatives aimed at enhancing cell ...

A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...

The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...

HotCopper favourite Mesoblast (ASX:MSB) has begun treating the first three children with skin graft-versus-host disease in ...

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Aged individuals and astronauts experience bone loss despite rigorous physical activity. Bone mechanoresponse is in-part ...

Scientists have unveiled a revolutionary method for mass-producing high-quality human mitochondria, potentially transforming ...

Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.

Final overall survival results show amivantamab plus lazertinib beat out osimertinib for first-line treatment of advanced ...

Cancer remains a leading cause of death globally, with lung cancer being particularly lethal. Despite advancements in diagnostics and therapies, the five-year survival rates for advanced tumors have ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first mesenchymal stromal cell ...